Psychiatry

A supplemental new drug application (sNDA) for vortioxetine (TRINTELLIX), a prescription medication for the treatment of adults with major depressive disorder (MDD), has been accepted by the FDA.

Increased access to proper mental health care is a key weapon in the battle against the deadly opioid epidemic, according to a recent study.

People with depression exhibit an unexpected increase in volume on the left side of the hypothalamus, the brain region responsible for physical wellbeing.

Patients receiving valbenazine for tardive dyskinesia reported high levels of satisfaction, even after up to 2 years of treatment.

Long-term treatment with valbenazine improved tardive dyskinesia symptoms over 48 weeks.

Results connecting breathlessness catastrophizing with reduced quality of life also have implications for populations with asthma or COPD.

Clinicians should encourage natural light exposure to reduce the risk of postpartum depression in women with third trimesters in the fall, study suggests.

Antipsychotic dose reductions can increase mental illness and all-cause hospitalizations, but the effects on tardive dyskinesia were unclear.

Research demonstrates that medication-assisted treatment for opioid addiction works, yet few have adopted it.

Recent studies questioned the benefits of second-generation antipsychotics, prompting researchers to reassess the risks of tardive dyskinesia from the use of first- and second-generation antipsychotics.

Study highlights differences in prescription of mental health medications for people living with HIV/AIDS.

Instances of sexual harassment are associated with high blood pressure and poor sleep for women in midlife, while sexual assault is associated with poor mental health and sleep.

Investigators stressed the importance of culturally competent care for patients with dementia and support for their caregivers.

The robustness of neural responses to positive and negative events may modify adolescent girls’ risk of depression, according to a new study.

Perampanel (FYCOMPA) has been approved for patients aged 4 years or older, who suffer from partial-onset seizures with or without secondarily generalized seizures, as both a tablet and oral suspension formulation.

A recent study investigating the HSPG2 gene in connection with tardive dyskinesia sheds new light on the root causes of the condition.

The FDA’s post-marketing review concludes a five-month speculation which began when CNN reported the Acadia Pharmaceutical antipsychotic therapy was associated with more than 700 deaths of patients with Parkinson disease since June 2016.

Study findings may facilitate new studies on the neural markers of tardive dyskinesia.

A quarter of surveyed second-year residents reported high emotional exhaustion and depersonalization. Nearly half reported weekly symptoms of burnout.

Almost 20% of young people with autism spectrum disorder (ASD) also were diagnosed with depression in a study that tracked participants into their 20s.

Physicians are primarily delivering disease management, rather than healing and care. The current system is a placing a strain on the practice.

A new meta-analysis aimed to quantify the effect, if any, of physician burnout on patient wellbeing. They found the links are strong and consequential.

After 10 days of transcranial magnetic stimulation, patients reported significant decreases in withdrawal symptoms like craving, quality of sleep, and mood status.

A study of primary care patients found that of patients screened for alcohol use, just 2.4% were also screened for depression. Men and racial/ethnic minorities were less likely to be screened for depression.

Interestingly, increased distress led to a higher risk of stroke for women, while distressed men had a higher risk of heart attack.

Deaths due to drug overdoses and suicides have contributed to decreasing US life expectancy, but other factors indicate that there is a deeper root cause driving these trends.

Preliminary findings from WTC Health Program are the first to make the connection among workers at "Ground Zero."

The therapy’s New Drug Application was accepted and granted Priority Review in May of this year, after having been granted Breakthrough Therapy designation in September 2016.

More than 2 million US outpatient visits and 3 million emergency department visits from 2005-2009 were accounted to children seeking care for mild TBI. Until now, no evidence-based clinical guidelines for pediatric mild TBI existed.

The New Drug Application is based on data from 5 phase 3 studies of the efficacy and safety of esketamine nasal spray for treatment-resistant depression.